ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?
Authors:
- 28 December 2006
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 113 (3) , 607-618
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family StudyHypertension, 2006
- Signaling via the Angiotensin-Converting Enzyme Enhances the Expression of Cyclooxygenase-2 in Endothelial CellsHypertension, 2005
- A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesityHuman Molecular Genetics, 2004
- The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE InhibitionHypertension, 2003
- Limited Proteolysis of Human Kidney Angiotensin-Converting Enzyme and Generation of Catalytically Active N- and C-Terminal DomainsBiochemical and Biophysical Research Communications, 1997
- Racial Difference in the Relationship of an Angiotensin I–Converting Enzyme Gene Polymorphism to Serum Angiotensin I– Converting Enzyme ActivityHypertension, 1996
- Enhanced Pressor Response to Angiotensin I in Normotensive Men With the Deletion Genotype (DD) for Angiotensin-Converting EnzymeHypertension, 1995
- Catalytic Properties of the Two Active Sites of Angiotensin I-Converting Enzyme on the Cell SurfaceBiochemical and Biophysical Research Communications, 1995
- Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.Hypertension, 1994
- Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatmentJournal Of Hypertension, 1992